literature

HIV mutation literature information.

Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis.

PMID: 28086929 2017 AIDS research and therapy

Table: L100I

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.

PMID: 28129253 2017 Journal of acquired immune deficiency syndromes (1999)

Result: After adjustment, participants on zidovudine at failure were more likely to have T215F, T215Y, M41L, K70R, D67N, L210W, type-1 thymidine analog, type-2 thymidine analog, and any thymidine analogue mutations (TAMs); those on tenofovir to have K65R, K70E, Y115F, and M184I; those on efavirenz to have K103N, P225H, Y188L, and L100I; and those on nevirapine to have Y181C and G190A.

Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.

PMID: 28481112 2017 Journal of medicinal chemistry

Abstract: Compound 25a was exceptionally potent against the whole viral panel, affording 3-4-fold enhancement of in vitro antiviral potency against WT, L100I, K103N, Y181C, Y188L, E138K, and K103N+Y181C and 10-fold enhancement against F227L+V106A relative to the reference drug etravirine (ETV) in the same cellular assay.

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).

PMID: 28891788 2017 HIV clinical trials

Method: Primary NNRTI-R substitutions assessed were V90I, A98G, L100I, K101E/H/P, K103N/S, V106A/I/M, V108I, E138A/G/K/Q/R, V179D/F/L/T, Y181C/I/V, Y188C/H/L, G190A/E/Q/S, H221Y, P225H, F227C, and M230I/L in RT.

Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaounde, Cameroon.

PMID: 29074854 2017 Scientific reports

Discussion: In the current study, analysis of RT and protease sequences from 109 HIV-infected and treatment-naive Cameroonians showed 8 (7.3%) with transmitted DRMs, including major resistance mutations to NRTIs (M184V and T215F) and NNRTIs (L100I, Y181C, K103N, V108I, and Y188L).

Discussion: The major NNRTIs resistance mutations identified in both treatment-naive and subjects on ART included L100I, Y181C, K103N

High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.

PMID: 28750647 2017 AIDS research and therapy

Table: L100I

Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study.

PMID: 29049402 2017 PloS one

Table: L100I

Discussion: But on the other side, a stable rate of selection was also observed for some NRTI mutations (such as Y115F, L210W) and several NNRTI mutations (such as L100I, K101E, P225H and M230L).

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.

PMID: 27120449 2016 PloS one

Method: RT-RAMs were identified and analyzed by using the Stanford Drug Resistance Database for V90I, A98G, L100I/V, K101E/P/Q/H/N, K103N/S/T/Q/E/H/R, V106A/M/I, V108I, E138A/K/Q/G/R, V179D/E/T/F/L, Y181C/I/V/S/F/G, M184I, Y188C/H/L/F, G190A/S/E/Q/C/V/T, H221Y,

Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.

PMID: 26651266 2016 AIDS research and human retroviruses

Method: Evidence of transmitted HIV-1 drug resistance (TDR) was defined by the presence of at least one surveillance drug resistance mutation (SDRM) from the consensus genotypic definition of Bennett et al., including major RVP-RAMs L100I+K103N, Y181C/I/V, Y188L, and M230L, and minor RPV-RAMs L100I, K103S, V106A, V179F, and G190A/E/S.

Method: In addition, we defined a list of minor RPV-RAMs that have been observed in in vitro or in vivo selection studies and are included in one or more of clinically widely used genotypic resistance interpretation algorithms ANRS (V24), Rega (V9.1.0), and HIVdb (V7.0.1), encompassing

HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naive and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.

PMID: 27119150 2016 PloS one

Discussion: Previously reported NNRTIs mutations for the 2004 to 2005 period in ARV drug-experienced subjects exposed to AZT or d4T + 3TC or ddI + EFV or NFV or IDV reported K103N at a lower frequency (4.9%), together with mutations L100I (1.2%) and Y318F (1.2%).

Browser Board

Co-occurred Entities

Filtrator